Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease

Table 5

Echocardiographic parameters in CKD patients and control group.

	CKD patients before treatment	CKD patients after treatment	Control group
	() (Me; 25–75%)	() (Me; 25–75%)	() (Me; 25–75%)
IVSd (mm)	16 (15.7–18.3)	15 (11.5–18.1)	12 (10.6–13.4)
LVM (g)	287.8 (217.7–357.9)	279.2 (183.2–355.2)	206 (163.8–248.2)
LVESd (mm)	41 (34.8–47.2)	39.9 (32.7–45.1)	36 (30.1–41.9)
LVEDd (mm)	48.5 (41.8–55.2)	47.1 (41.5–52.7)	40 (32.6–47.4)
LA (mm)	41.9 (39.2–44.6)	41.3 (37.1–43.5)	31 (28.8–33.2)
EF (%)	35 (30–42)	42 (35–48)	60 (51–69)
LVH (%)	100	100	20
LVDD (%)	96.7	91.6	27

⁢ versus control group; versus CKD patients before treatment.
CKD = chronic kidney disease, IVSd = intraventricular septal diameter, LVM = left ventricular mass, LVESd = left ventricular end systolic diameter, LVEDd = left ventricular end diastolic diameter, LA = left atrial diameter, EF = left ventricular ejection fraction, LVH = left ventricular hypertrophy, and LVDD = left ventricular diastolic dysfunction.